Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Withdrawn 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Hematologic Neoplasms 2Pain 1

Interventions

Cytarabine 35Cyclophosphamide 30fludarabine phosphate 24fludarabine 24Rituximab 20Azacitidine 19Methotrexate 17venetoclax 16Peripheral Blood Stem Cell Transplantation 14Dasatinib 12Bendamustine Hydrochloride 12ibrutinib 11Filgrastim 11Busulfan 11Whole-Body Irradiation 10Granulocyte Colony-Stimulating Factor 10Tacrolimus 9Radiotherapy 9Lenalidomide 8Idarubicin 8Decitabine 8Vincristine 7Etoposide 7Dexamethasone 7Daunorubicin 7Cyclosporine 7merphos 6Prednisone 6Melphalan 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Olanzapine × Other hematologic neoplasm × Clear all
NCT05403580 2024-05-06

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer

Mayo Clinic

Phase 3 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

NCT00737191 2012-03-09

Opioids With or Without Olanzapine in Treating Patients With Moderate to Severe Cancer Pain

Mayo Clinic

Phase NA Withdrawn
Other hematologic neoplasm

Pain, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡